IAVI G002
Status:Ongoing
Phase:I
Principal Investigator(s):Dagna Laufer
Objective:A Phase 1, Randomized, First-in-human, Open-label Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core) in HIV-1 Uninfected Adults in Good General HealthLast edited June 10, 2022
Prevention Option(s):HIV Vaccine
Study Design:Open label, Randomized
Arms and Assigned Interventions
DescriptionBiological: eOD-GT8 60mer mRNA Vaccine
100µg, Intramuscularly
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionBiological: Core-g28v2 60mer mRNA Vaccine
100µg, Intramuscularly
Biological: eOD-GT8 60mer mRNA Vaccine
100µg, Intramuscularly
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionBiological: Core-g28v2 60mer mRNA Vaccine
100µg, Intramuscularly
Biological: eOD-GT8 60mer mRNA Vaccine
100µg, Intramuscularly
Mode of DeliveryIntramuscular
ARMsExperimental
DescriptionBiological: Core-g28v2 60mer mRNA Vaccine
100µg, Intramuscularly
Mode of DeliveryIntramuscular
ARMs
Official Code:
NCT05001373
Trial Sponsors:
Emory University, Fred Hutchinson Cancer Research Center, George Washington University, IAVI, ModernaTX Inc., The University of Texas at San Antonio
Start Date
End Date
November 12, 2021
April 11, 2023
Enrollment:56
Age range:
18 Years ↔
50 Years
Population:Cisgender Men, Cisgender Women